SYNACT Stock Overview
A clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
SynAct Pharma AB Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | SEK 8.70 |
52 Week High | SEK 124.60 |
52 Week Low | SEK 4.98 |
Beta | 0.66 |
11 Month Change | -8.42% |
3 Month Change | 30.73% |
1 Year Change | -90.92% |
33 Year Change | -91.33% |
5 Year Change | -0.23% |
Change since IPO | 67.31% |
Recent News & Updates
Recent updates
Here's Why We're Watching SynAct Pharma's (STO:SYNACT) Cash Burn Situation
Sep 04Is SynAct Pharma (NGM:SYNACT) In A Good Position To Deliver On Growth Plans?
Jan 18Here's Why We're Not Too Worried About SynAct Pharma's (NGM:SYNACT) Cash Burn Situation
Sep 03SynAct Pharma (NGM:SYNACT) Is In A Good Position To Deliver On Growth Plans
Apr 07Companies Like SynAct Pharma (NGM:SYNACT) Are In A Position To Invest In Growth
Dec 23Shareholder Returns
SYNACT | SE Biotechs | SE Market | |
---|---|---|---|
7D | 2.5% | -5.4% | -4.2% |
1Y | -90.9% | 18.1% | 12.5% |
Return vs Industry: SYNACT underperformed the Swedish Biotechs industry which returned 21% over the past year.
Return vs Market: SYNACT underperformed the Swedish Market which returned 17% over the past year.
Price Volatility
SYNACT volatility | |
---|---|
SYNACT Average Weekly Movement | 7.4% |
Biotechs Industry Average Movement | 8.7% |
Market Average Movement | 5.8% |
10% most volatile stocks in SE Market | 12.2% |
10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: SYNACT has not had significant price volatility in the past 3 months.
Volatility Over Time: SYNACT's weekly volatility has decreased from 21% to 7% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 5 | Jeppe Ovlesen | synactpharma.com |
SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases.
SynAct Pharma AB Fundamentals Summary
SYNACT fundamental statistics | |
---|---|
Market cap | SEK 359.28m |
Earnings (TTM) | -SEK 190.84m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.9x
P/E RatioIs SYNACT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SYNACT income statement (TTM) | |
---|---|
Revenue | SEK 0 |
Cost of Revenue | SEK 0 |
Gross Profit | SEK 0 |
Other Expenses | SEK 190.84m |
Earnings | -SEK 190.84m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 20, 2024
Earnings per share (EPS) | -4.62 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did SYNACT perform over the long term?
See historical performance and comparison